Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
about
Economic burden of hepatitis C-associated diseases in the United States.Cost-effectiveness and population outcomes of general population screening for hepatitis C.Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.Treating hepatitis C in the prison population is cost-saving.
P2860
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Peginterferon alfa-2a versus p ...... ns Affairs Health Care System.
@en
Peginterferon alfa-2a versus p ...... ns Affairs Health Care System.
@nl
type
label
Peginterferon alfa-2a versus p ...... ns Affairs Health Care System.
@en
Peginterferon alfa-2a versus p ...... ns Affairs Health Care System.
@nl
prefLabel
Peginterferon alfa-2a versus p ...... ns Affairs Health Care System.
@en
Peginterferon alfa-2a versus p ...... ns Affairs Health Care System.
@nl
P2093
P2860
P356
P1433
P1476
Peginterferon alfa-2a versus p ...... ns Affairs Health Care System.
@en
P2093
Daniel C Malone
Edward P Armstrong
Grant H Skrepnek
Wei-Shi Yeh
P2860
P304
P356
10.1592/PHCO.27.6.813
P407
P577
2007-06-01T00:00:00Z